Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 antibody + adenovirus type 5 + chemotherapy for primary metastatic osteosarcoma
ChiCTR2000037525Phase 2Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and Oncorine in osteosarcoma (OS), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: event-free survival. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
sintilimabOncorine
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR2000037525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037525.